Abstract
ObjectiveRandomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have